Literature DB >> 20144472

Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System.

Linda Cox1, Desiree Larenas-Linnemann, Richard F Lockey, Giovanni Passalacqua.   

Abstract

Subcutaneous allergen immunotherapy (SCIT) is an effective treatment for allergic rhinitis, asthma and venom hypersensitivity and has the potential of producing serious life-threatening anaphylaxis. Adverse reactions are generally classified into 2 categories: local reactions, which can manifest as redness, pruritus, and swelling at the injection site, and systemic reactions (SRs). SRs can range in severity from mild rhinitis to fatal cardiopulmonary arrest. Early administration of epinephrine, which is the treatment of choice to treat anaphylaxis, may prevent the progression of an SR to a more serious life-threatening problem. Although there is little debate about using epinephrine to treat a SCIT SR, there is a lack of consensus about when it should be first used. A uniform classification system for grading SCIT SRs will be helpful in assessing more accurately when epinephrine should be administered. The primary purpose of this article is to discuss the proposed grading system for SCIT SRs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20144472     DOI: 10.1016/j.jaci.2009.10.060

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  95 in total

Review 1.  Subcutaneous and sublingual immunotherapy for allergic rhinitis: what is the evidence?

Authors:  Sarah K Wise; Rodney J Schlosser
Journal:  Am J Rhinol Allergy       Date:  2012 Jan-Feb       Impact factor: 2.467

2.  Multiple courses of immunotherapy with different immune cell types for patients with hepatocellular carcinoma after microwave ablation.

Authors:  Ming-An Yu; Ping Liang; Xiao-Ling Yu; Zhi-Yu Han; Xue-Juan Dong; Y U Wang; Chao Cheng; Xin Li
Journal:  Exp Ther Med       Date:  2015-08-14       Impact factor: 2.447

3.  Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.

Authors:  Guy W Scadding; Moises A Calderon; Mohamed H Shamji; Aarif O Eifan; Martin Penagos; Florentina Dumitru; Michelle L Sever; Henry T Bahnson; Kaitie Lawson; Kristina M Harris; Audrey G Plough; Joy Laurienzo Panza; Tielin Qin; Noha Lim; Nadia K Tchao; Alkis Togias; Stephen R Durham
Journal:  JAMA       Date:  2017-02-14       Impact factor: 56.272

4.  Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2.

Authors:  Tolly G Epstein; Gary M Liss; Karen Murphy-Berendts; David I Bernstein
Journal:  Ann Allergy Asthma Immunol       Date:  2011-06-17       Impact factor: 6.347

Review 5.  Immunotherapy for pet allergies.

Authors:  Tuomas Virtanen
Journal:  Hum Vaccin Immunother       Date:  2017-12-21       Impact factor: 3.452

Review 6.  Update on oral immunotherapy for egg allergy.

Authors:  François Graham; Natacha Tardio; Louis Paradis; Anne Des Roches; Philippe Bégin
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 7.  Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles.

Authors:  Harold S Nelson; Moises A Calderon; David I Bernstein; Thomas B Casale; Stephen R Durham; Jens S Andersen; Robert Esch; Linda S Cox; Hendrik Nolte
Journal:  Curr Allergy Asthma Rep       Date:  2017-03       Impact factor: 4.806

Review 8.  The risk and management of anaphylaxis in the setting of immunotherapy.

Authors:  Phil Lieberman
Journal:  Am J Rhinol Allergy       Date:  2012 Nov-Dec       Impact factor: 2.467

Review 9.  Immunotherapy safety: what have we learned from surveillance surveys?

Authors:  Jennifer A Kannan; Tolly G Epstein
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

Review 10.  Allergen immunotherapy for allergic respiratory diseases.

Authors:  Antonio Cappella; Stephen R Durham
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.